Abstract
Determining a patient’s readiness to adhere well prior to the start of ART provides an opportunity to address adherence barriers before poor pill taking habits form, and ultimately improve clinical outcomes and resource utilization. Three methods of measuring adherence readiness and their comparative utility in predicting early ART adherence were examined in a sample of 176 patients preparing to start ART. Data were analyzed data from a randomized controlled trial of a cognitive-behavioral adherence intervention. Three measures of pre-ART adherence readiness (provider estimate, 1 week vitamin practice trials, and self-report [HIV Medication Readiness Scale; Transtheoretical Stages of Change item (TSOC)] were examined in association with measures of (1) ART initiation, (2) ART retention, (3) mean electronic dose-taking adherence, and (4) achievement of optimal (85+ % dose-taking) adherence, over the first 3 months of ART. Of the 176 patients, 166 (94.3%) started ART; 124 (74.7% of those who started ART; 70.5% of whole sample) completed the first 3 months of ART. Among the 124 still on ART at month 3, mean dose-taking adherence was 79.3%, and 62 (35.2% of whole sample) achieved optimal adherence. The provider estimate was the only readiness measure significantly associated with each of the four measures of early ART adherence, and it had the highest concordance statistics (71% PPV and 62.3% NPV) with optimal early ART adherence. Practice trial adherence was only associated with ART initiation and retention. Dose-taking adherence over 3 months was significantly correlated with the provider estimate and the two self-reports. Each method of early treatment adherence has its own utility, but the provider estimate had the best overall performance in predicting early ART adherence.
Similar content being viewed by others
References
Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother. 2011;45(3):372–9.
Pasternak AO, de Bruin M, Jurriaans S, Bakker M, Berkhout B, Prins JM, et al. Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis. 2012;206(9):1443–52.
Bangsberg DR, Hecht FM, Clague H, Charlebois ED, Ciccarone D, Chesney M, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26(5):435–42.
Bouton ME. A learning theory perspective on lapse, relapse, and the maintenance of behavior change. Health Psychol. 2000;19(1S):57.
AIDSinfo. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. 2019. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/37/whats-new-in-the-guidelines.
Sylvain H, Delmas P. Readiness in HIV treatment adherence: a matter of confidence. An exploratory study. Open AIDS J. 2011;5:119.
Gross R, Bilker WB, Friedman HM, Coyne JC, Strom BL. Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. AIDS. 2002;16(13):1835–7.
Miller LG, Liu H, Hays RD, Golin CE, Beck CK, Asch SM, et al. How well do clinicians estimate patients’ adherence to combination antiretroviral therapy? J Gen Intern Med. 2002;17(1):1–11.
Wagner G. Placebo practice trials: the best predictor of adherence readiness for HAART among drug users? HIV Clin Trials. 2003;4(4):269–81.
Prochaska JO. Assessing how people change. Cancer. 1991;67(S3):805–7.
Willey C, Redding C, Stafford J, Garfield F, Geletko S, Flanigan T, et al. Stages of change for adherence with medication regimens for chronic disease: development and validation of a measure. Clin Ther. 2000;22(7):858–71.
Konkle-Parker DJ. A motivational intervention to improve adherence to treatment of chronic disease. J Am Acad Nurse Pract. 2001;13(2):61–8.
Grimes RM, Grimes DE. Readiness, trust, and adherence: a clinical perspective. J Int Assoc Provid AIDS Care (JIAPAC). 2013;12(3):185–94.
Wagner GJ, Linnemayr S, Ghosh-Dastidar B, Currier JS, Hoffman R, Schneider S. Supporting treatment adherence readiness through training (START) for patients with HIV on antiretroviral therapy: study protocol for a randomized controlled trial. Trials. 2016;17(1):162.
Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357–66.
Balfour L, Tasca GA, Kowal J, Corace K, Cooper CL, Angel JB, et al. Development and validation of the HIV Medication Readiness Scale. Assessment. 2007;14(4):408–16.
Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot. 1997;12(1):38–48.
Highstein GR, Willey C, Mundy LM. Development of stage of readiness and decisional balance instruments: tools to enhance clinical decision-making for adherence to antiretroviral therapy. AIDS Behav. 2006;10:563–73.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Azhar, G.S., Schneider, S., Hoffman, R. et al. Evaluating Measures of Pre-ART Adherence Readiness Through Associations with ART Adherence in the Early Months of Treatment. AIDS Behav 24, 648–654 (2020). https://doi.org/10.1007/s10461-019-02708-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-019-02708-0